Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome
文献类型：期刊论文
| 作者 | Wang, Shun7,8; Lin, Feifei6 ; Zhang, Chengxi7,8; Gao, Dan7,8; Qi, Zhuocao7,8; Wu, Suwan7,8; Wang, Wantao7,8; Li, Xiaoqian7,8; Pan, Lingyun5; Xu, Yanwu4
|
| 刊名 | JOURNAL OF ETHNOPHARMACOLOGY
 |
| 出版日期 | 2024-01-30 |
| 卷号 | 319页码:13 |
| ISSN号 | 0378-8741 |
| 关键词 | Xuanbai Chengqi Decoction Acute lung injury NLRP3 inflammasome Pyroptosis |
| DOI | 10.1016/j.jep.2023.117227 |
| 通讯作者 | Tan, Bo(tbot@163.com) ; Yang, Aidong(aidongy@126.com) |
| 英文摘要 | Ethnopharmacological relevance: Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a prevalent critical respiratory disorder caused mostly by infection and other factors. However, effective drug therapies are currently lacking. Xuanbai Chengqi Decoction (XCD), a traditional Chinese medicine (TCM) prescription, is commonly employed to treat lung diseases. It has been recommended by Chinese health authorities as one of the TCM prescriptions for COVID-19. Nonetheless, its underlying mechanism for the treatment of ALI has not been fully understood.Aim of the study: The study aims to investigate the therapeutic effect of XCD on lipopolysaccharide (LPS) -induced ALI in mice and explore its anti-inflammatory mechanism involving pyroptosis.Materials and methods: Ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) was employed to identify the active compounds of XCD, and quantitative analysis of the main compounds was conducted. Male C57BL/6J mice were given different doses of XCD (4.5 and 9.0 g/kg/day) or dexamethasone (5 mg/kg/day) by oral gavage for 5 consecutive days. Subsequently, ALI was induced by injecting LPS (20 mg/kg) intraperitoneally 2 h after the last administration, and serum and lung tissues were collected 8 h later. J774A.1 cells were pretreated with different doses of XCD (100, 200, 400 mu g/ml) for 12 h, then incubated with LPS (1 mu g/ml) for 4 h and ATP (1 mM) for 2 h to induce pyroptosis. Supernatant and cells were collected. Moreover, J774A.1 cells were transfected with an NLRP3 overexpression plasmid for 24 h, followed by subsequent experiments with XCD (400 mu g/ml). Lung histopathological changes were evaluated using hematoxylin and eosin (HE) staining. To assess the efficacy of XCD on ALI/ARDS, the levels of inflammatory factors, chemokines, and proteins associated with NLRP3 inflammasome signaling pathway were evaluated.Results: XCD was found to ameliorate lung inflammation injury in ALI mice, and reduce the protein expression of TNF-alpha, IL-1 beta, and IL-6 in both mouse serum and J774A.1 cell supernatant. Meanwhile, XCD significantly decreased the mRNA levels of IL-1 beta, pro-IL-1 beta, CXCL1, CXCL10, TNF-alpha, NLRP3, NF-kappa B P65, and the protein expression of NLRP3, Cleaved-Caspase1, and GSDMD-N in the lung and J774A.1 cells. These effects were consistent with the NLRP3 inhibitor MCC950. Furthermore, overexpression of NLRP3 reversed the anti-inflammatory effect of XCD.Conclusion: The therapeutic mechanism of XCD in ALI treatment may involve alleviating inflammatory responses in lung tissues by inhibiting the activation of the NLRP3 inflammasome-mediated pyroptosis in macrophages. |
| WOS关键词 | AMYGDALIN ; BIOLOGY ; CARE |
| 资助项目 | Shanghai Shuguang Hospital Siming Project[2021LK075] ; [SGXZ-201907] |
| WOS研究方向 | Plant Sciences ; Pharmacology & Pharmacy ; Integrative & Complementary Medicine |
| 语种 | 英语 |
| 出版者 | ELSEVIER IRELAND LTD |
| WOS记录号 | WOS:001087802100001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/307572]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Tan, Bo; Yang, Aidong |
| 作者单位 | 1.Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Zhangheng Rd 528, Shanghai 201203, Peoples R China 2.Shanghai Univ Tradit Chinese Med, Sch Tradit Chinese Med, Cailun Rd 1200, Shanghai 201203, Peoples R China 3.Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 201203, Peoples R China 4.Shanghai Univ Tradit Chinese Med, Sch Integrat Med, Shanghai 201203, Peoples R China 5.Shanghai Univ Tradit Chinese Med, Expt Ctr Sci & Technol, Shanghai 210203, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 7.Shanghai Inst Infect Dis & Biosecur, Shanghai 201203, Peoples R China 8.Shanghai Univ Tradit Chinese Med, Sch Tradit Chinese Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Shun,Lin, Feifei,Zhang, Chengxi,et al. Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome[J]. JOURNAL OF ETHNOPHARMACOLOGY,2024,319:13. |
| APA | Wang, Shun.,Lin, Feifei.,Zhang, Chengxi.,Gao, Dan.,Qi, Zhuocao.,...&Yang, Aidong.(2024).Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome.JOURNAL OF ETHNOPHARMACOLOGY,319,13. |
| MLA | Wang, Shun,et al."Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome".JOURNAL OF ETHNOPHARMACOLOGY 319(2024):13. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。